XORTX Therapeutics Inc. (XRTX) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.24
+6% vs avg
5yr avg: 0.23
30Y Low0.1·High3.8
ROE
↓
-97.0%
↑-45% vs avg
5yr avg: -66.9%
30Y Low-246%·High-23%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XRTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
XORTX Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $737996 | $532172 | $650541 | $915569 | $2M | $4M | $2M | $2M | $1M | — | — |
| Enterprise Value | $-93055 | $-601749 | $-2851280 | $-2520587 | $-8204267 | $-10832540 | $2M | $2M | $997434 | — | — |
| P/E Ratio → | -0.19 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.24 | 0.19 | 0.14 | 0.20 | 0.31 | 0.31 | 1.44 | — | 3.78 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
XRTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
XRTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -97.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -97.0% | -97.0% | -96.2% | -49.1% | -69.2% | -22.9% | -246.0% | -1146.6% | -1174.3% | — | — |
| ROA | -77.6% | -77.6% | -79.9% | -32.1% | -47.0% | -16.8% | -76.0% | -53.5% | -430.1% | -122.7% | -170.7% |
| ROIC | -226.0% | -226.0% | -338.2% | — | — | — | -187.6% | — | — | — | — |
| ROCE | -118.9% | -118.9% | -113.2% | -59.9% | -89.8% | -32.1% | -207.2% | -739.5% | -293.1% | — | — |
XRTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $1M exceeds total debt of $51111, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — | 0.13 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -0.73 | -0.74 | -1.48 | -1.13 | -0.14 | — | -0.67 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 2.68 | — |
| Interest Coverage | — | — | — | — | — | -665.28 | -94.07 | -15.92 | -48.82 | -28.71 | -47.00 |
Net cash position: cash ($1M) exceeds total debt ($51111)
XRTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.61x means XORTX Therapeutics Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 13.80x to 1.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.61 | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 | 1.99 | 0.48 | 1.09 | 0.06 | 0.03 |
| Quick Ratio | 1.61 | 1.61 | 3.53 | 13.80 | 7.21 | 28.78 | 2.00 | 0.35 | 1.09 | 0.06 | 0.03 |
| Cash Ratio | 1.44 | 1.44 | 3.26 | 11.69 | 6.90 | 26.74 | 0.17 | 0.05 | 0.29 | 0.06 | 0.23 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | 0.12 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
XRTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
XORTX Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $189385 | $115140 | $79270 | $59195 | $43765 | $29620 | $25035 | $25035 | $8505 | $7135 |
Peer Comparison
Compare XRTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XRTXYou | $737996 | -0.2 | — | — | — | — | -97.0% | -226.0% | — |
 ARDX | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 CPRX | $4B | 18.6 | 10.5 | 18.3 | 85.2% | 43.8% | 25.5% | 83.9% | 0.0 |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See XRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XRTX vs ARDX
Side-by-side business, growth, and profitability comparison vs Ardelyx, Inc..
Start ComparisonXRTX — Frequently Asked Questions
Quick answers to the most common questions about buying XRTX stock.
What is XORTX Therapeutics Inc.'s P/E ratio?
XORTX Therapeutics Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
What is XORTX Therapeutics Inc.'s ROE?
XORTX Therapeutics Inc.'s return on equity (ROE) is -97.0%. The historical average is -101.2%.
Is XRTX stock overvalued?
Based on historical data, XORTX Therapeutics Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.